Orion OyjORINF +4.81%97 Return-on-Tangible-Equity is 35.38% as of Mar. 2026, which is 12% below its 10-year median of 40.32. GuruFocus rates ORINF with a GF Score™ of 97/100 and a GF Value™ of $80.82. The stock has 3 warning signs investors should review. Among 898 Drug Manufacturers companies, Orion Oyj ranks better than 91.65% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Orion Oyj's annualized net income for the quarter that ended in Mar. 2026 was $418 Mil. Orion Oyj's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $1,182 Mil. Therefore, Orion Oyj's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 35.38%.
The historical rank and industry rank for Orion Oyj's Return-on-Tangible-Equity or its related term are showing as below:
ORINF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 27.88 Med: 40.32 Max: 59
Current: 59
During the past 13 years, Orion Oyj's highest Return-on-Tangible-Equity was 59.00%. The lowest was 27.88%. And the median was 40.32%.
ORINF's Return-on-Tangible-Equity is ranked better than 91.65% of 898
companies
in the Drug Manufacturers industry
Industry Median: 7.88
vs ORINF: 59.00
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Orion Oyj Return-on-Tangible-Equity Related Terms
Orion Oyj Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Orion Oyj's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORINF vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, Orion Oyj's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Orion Oyj's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 35.38% mean?
Orion Oyj (ORINF) has a Return-on-Tangible-Equity of 35.38% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Orion Oyj and its competitors. This is 12% below median its historical median of 40.32. Over the past decade, Orion Oyj's Return-on-Tangible-Equity has ranged from 27.88 to 59.00. According to the industry distribution chart, Orion Oyj ranks #75 out of 898 companies in the Drug Manufacturers industry, placing it in the top 8.4%.
Is Orion Oyj's Return-on-Tangible-Equity too high?
Orion Oyj's current Return-on-Tangible-Equity of 35.38% is 12% below median its 10-year median of 40.32. Over the past 10 years, this metric has ranged from a low of 27.88 to a high of 59.00. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.88. Orion Oyj's value of 35.38% is 349% above this industry median. Based on the distribution chart, Orion Oyj ranks #75 out of 898 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orion Oyj has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #75 out of 898 companies for Return-on-Tangible-Equity. This places Orion Oyj in the top 8% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.88. Orion Oyj's value of 35.38% is 349% above this benchmark. Historically, Orion Oyj's own Return-on-Tangible-Equity has ranged from 27.88 to 59.00 over the past decade. While the company's 10-year median is 40.32 vs. the industry median of 7.88, Orion Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current Return-on-Tangible-Equity of 35.38% is 349% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Orion Oyj and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current Return-on-Tangible-Equity is 35.38%, which is 12% below median its own 10-year median of 40.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Orion Oyj (ORINF) has a current Return-on-Tangible-Equity of 35.38%. The stock's GF Value™ is $80.82, compared to a current price of $82.75 — trading 2.4% above its estimated fair value. The current Return-on-Tangible-Equity is 35.38%, which is 12% below median its 10-year median of 40.32 and 349% above the Drug Manufacturers industry median of 7.88. Orion Oyj's overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Orion Oyj (ORINF), the current Return-on-Tangible-Equity is 35.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (ORINF) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued.
The current stock price of $82.75 is trading 2.4% above its estimated GF Value™ of $80.82.
Key valuation signals for ORINF:
Return-on-Tangible-Equity: 35.38% (12% below median its 10-year median of 40.32)
GF Value™: $80.82 vs. price of $82.75 (2.4% above fair value)
Industry Position: 349% above the Drug Manufacturers median (#75 of 898)
No single metric tells the full story. See the ORINF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
97GF Score
Get the complete analysis for ORINF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORINF has been successfully added to your 
